MarginsXMarginsX
Home › Markets › Health Care › DNA

Ginkgo Bioworks Holdings Inc. (DNA)

DNA trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$8.50
-11.55% on the day
Market cap
$551.0M
Small cap
Revenue · 2025
$170.2M
-25.1% on 2024
Net income · 2025
-$312.8M
-183.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1830214/000162828026012346/0001628280-26-012346-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerDNA on NYSE
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001830214
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$170.2M
Net income-$312.8M
Operating income-$315.3M
Net margin-183.8%
Operating margin-185.3%
Revenue growth-25.1%
Cash$167.2M
Total assets$1.1B
P/E (computed)Net income was not positive
P/S (computed)3.2×

Warning signs

Cash runway
6.1 months
$84.5M cash at September 30, 2026
Share count, 1 year
+7.0%
2025-10-31 to 2026-10-30
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$2.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$84.5M cash; operating cash flow -$41.7M a quarter.Report 2026-09-30
Shares outstanding64,825,013 (2026-10-30); 60,590,219 a year earlier.Cover page 2026-10-30
Reverse splits, 3 years1; latest 1-for-40 on 2024-08-20Source 2024-08-20
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $2.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$27.7M-$41.0M-$28.3M$84.5MNo debt tags$130.8M10-Q 2026-11-09
Q2 2026
2026-06-30
$20.2M-$46.7M-$44.3M$84.5MNo debt tags$132.4M10-Q 2026-08-06
Q1 2026
2026-03-31
$19.5M-$82.6M-$46.7M$143.9MNo debt tags$151.4M10-Q 2026-05-07
Q4 2025
2025-12-31
$63.4M-$80.8M-$47.7M$167.2MNo debt tags$170.2M10-K 2026-02-26
Q3 2025
2025-09-30
$29.4M-$80.8M-$31.6M$111.1MNo debt tags$150.6M10-Q 2026-11-09
Q2 2025
2025-06-30
$39.1M-$60.3M-$40.3M$203.6MNo debt tags$210.3M10-Q 2026-08-06
Q1 2025
2025-03-31
$38.2M-$91.0M-$51.5M$312.4MNo debt tags$227.3M10-Q 2026-05-07
Q4 2024
2024-12-31
$43.8M-$107.5M-$42.4M$561.6MNo debt tags$227.0M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-09-04
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-14.9%
1 month-18.3%
3 months+32.7%
Year to date+15.6%
1 year+20.1%
From 52-week high-35.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
IAMIambic Therapeutics Inc.$11.85-9.54%$561.7M
SANASana Biotechnology Inc.$1.88-6.93%$563.3M
VALNValneva SE$5.65-0.18%$536.1M
ENTXEntera Bio Ltd.$3.02-2.89%$525.9M
ETRAElectra Therapeutics Inc.$8.31-6.00%$522.4M
SRZNSurrozen Inc.$32.32+2.25%$616.1M
CGEMCullinan Therapeutics Inc.$9.50-7.59%$616.7M
RGNXREGENXBIO Inc.$7.32-4.19%$484.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier